Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 74 Significant growth in GLP-1 market with leading market share for VictozaⓇ Global GLP-1 market value and share of total diabetes care market value Novo Nordisk GLP-1 value market share leading in all regions except Japan & Korea ☐ Novo Nordisk GLP-1 value market share VictozaⓇ bDKK albiglutide¹ 80 70 60 exenatide 50 launch 40 30 20 10 0 2005 OzempicⓇ dulaglutide exenatide GLP-1 share of total diabetes care market FDA/EMA statement on 16% bDKK 60 45% pancreatic safety³ 14% 50 Dulaglutide Article on 12% launch pancreatic safety 40 10% of incretins² 8% 30 VICTOZA liraglutide injection 6% 20 - 4% 10 55% 2% 34% 0% 0 2009 2013 2014 2018 North America Region Europe 69% 44% Region Region Region Region J&K LATAM AAMEO China 82% 1 Manufacturing and sale of albiglutide expected to be discontinued by July 2018 2 Butler et al, Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors, Diabetes, Vol. 62, Jul 2013 3 Egan et al, Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment, The New England Journal of Medicine 370;9, 27 Feb 2014 Source: IQVIA MIDAS, monthly data, Aug 2018 (Note: IQVIA data does not adequately capture rebates resulting in an overstatement of market value) FDA: US Food and Drug Administration; EMA: European Medicines Agency AAMEO: Africa, Asia, the Middle-East and Oceania; J&K: Japan & Korea; LATAM: Latin America Source: Reported sales until August 2018; IQVIA MIDAS, Aug 2018 novo nordisk

View entire presentation